Patents Examined by Amelia Owens
  • Patent number: 7141681
    Abstract: The invention relates to a continuous process for preparing dihydropyrones of general formula I, wherein the groups R1 and R2 have the meanings described herein.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: November 28, 2006
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Oliver Meyer, Markus Sauter, Mark Goehlich
  • Patent number: 7141669
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: November 28, 2006
    Assignee: Pfizer Inc.
    Inventors: Philip A. Carpino, David A. Griffith
  • Patent number: 7141564
    Abstract: Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: November 28, 2006
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Gerald Brooks, David Thomas Davies, Graham Elgin Jones, Roger Edward Markwell, Neil David Pearson
  • Patent number: 7138428
    Abstract: Disclosed herein are an acetone-extracted product obtained from gamboge resin and compounds further purified from said acetone-extracted product, including a new compound called formoxanthone A. The acetone-extracted product and the further purified compounds have been demonstrated to have activities in inhibiting the growth of tumor/cancer cells. Also disclosed are the processes for obtaining said further purified compounds, and the uses of the acetone-extracted product and the further purified compounds in the preparation of pharmaceutical composition for inhibiting the growth of tumor/cancer cells.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: November 21, 2006
    Assignee: Taiwan Sunpan Biotechnology Development Company, Ltd.
    Inventors: Sen-Bin Lee, Chiu-Ming Chen
  • Patent number: 7135482
    Abstract: Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: November 14, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Qiyue Hu, Ted William Johnson, Atsuo Kuki, Michael Bruno Plewe, Dawn Marie Nowlin, Hai Wang, Junhu Zhang
  • Patent number: 7132446
    Abstract: Certain proanthocyanidins found in various wines, grape juice, and other plant extracts exhibit endothelium-dependent vasorelaxing activity that involves increased nitric oxide production by endothelial cells. The smallest procyanidins (PCs) possessing substantial EDR activity were isolated from grape seeds. A dimer di-gallate (epicatechin-galloyl-epicatechin-gallate) was purified from concord grape seed extracts by Toyopearl TSK-40 gel chromatography, HPLC and electrospray FTMS. Further characterization was achieved using tannase treatment and acid thiolysis. This compound had an EC50 for vasorelaxation of 0.67±0.04 ?g/ml when tested for endothelium-dependent relaxing activity in phenylephrine pre-contracted rat aortic rings.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 7, 2006
    Assignee: University of South Florida
    Inventors: David F. Fitzpatrick, Rebecca O'Malley
  • Patent number: 7132447
    Abstract: The present invention is comprised of culturing microorganism having ability to produce FKI-1083 substance represented by the formula: in a medium, accumulating FKI-1083 substance in the cultured medium, and isolating FKI-1083 substance from the cultured mass. The thus obtained FKI-1083 substance has growth inhibitory activities against microorganisms, nematodes and arthropods, and is useful as anthelmintic and insecticide.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: November 7, 2006
    Assignee: The Kitasato Institute
    Inventors: Satoshi Omura, Kazuro Shiomi, Rokuro Masuma
  • Patent number: 7129357
    Abstract: In one embodiment, the present application discloses a process for making the compound of the formula:
    Type: Grant
    Filed: September 13, 2004
    Date of Patent: October 31, 2006
    Assignee: Schering Corporation
    Inventors: David R. Andrews, Suhan Tang, Wenxue Wu, Sami Y. Kalliney, Anantha Sudhakar, Christopher Nielsen
  • Patent number: 7119100
    Abstract: The present invention relates to oripavine derivatives of formula (I), wherein R1 is hydrogen or methyl, R2 is methyl, cyclopropyl methyl, cyclobutyl methyl or allyl, R3 is thiophenyl ethyl or cycloalkyl methyl where the cycloalkyl has 3 to 6 carbon atoms, or non-toxic pharmaceutically acceptable salts thereof. These compounds can be used for the preparation of analgesics or abstinence agents of opium habit-forming drugs.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: October 10, 2006
    Assignees: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A. China, Zhejiang Xianju Pharmaceuticals Co. Ltd.
    Inventors: Bohua Zhong, Zehui Gong, Yaping Wang, Yongshao Liu
  • Patent number: 7115662
    Abstract: Disclosed are the compounds of formula I wherein R is methyl or ethyl; R1 is chloro or fluoro; R2 is hydrogen or fluoro; R3 is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4 is hydrogen or fluoro; and R5 is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: October 3, 2006
    Assignee: Novartis AG
    Inventors: Roger A Fujimoto, Leslie W McQuire, Benjamin B Mugrage, John H Van Duzer, Daqiang Xu
  • Patent number: 7115606
    Abstract: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: October 3, 2006
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: Steven B. Landau, Cheryl L. Miller, Matthew O. Fraser
  • Patent number: 7115655
    Abstract: The present invention relates to compounds of the following formula (I) or pharmaceutically acceptable salts thereof. The present invention also relates to use for a cognitive-enhancing agent of compounds of the following formula (I) or pharmaceutically acceptable salts thereof and to a process for preparing the same. Further, the present invention relates to use for a congnitive-enhancing agent of decursin of the following formula (II) or pharmaceutically acceptable salts thereof. In addition, the present invention relates to extracts of Angelica gigantis Radix comprising decursin of the following formula (II), having cognitive-enhancing effects.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: October 3, 2006
    Assignee: Elcom Biotechnology, Co. Ltd.
    Inventors: Jeong-Seon Yoon, Ji-Young Lee, Young-Choong Kim, Ki-Yong Lee, Sang-Hyun Sung, Hak-Joong Kim, So-Young Kang
  • Patent number: 7115621
    Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents as inhibitors of phosphodiesterase 5 cardiovascular disorders
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: October 3, 2006
    Assignee: Lilly Icos LLC
    Inventors: Jason S. Sawyer, Mark W. Orme, James D. Copp
  • Patent number: 7112592
    Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: September 26, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Maxime Lampilas, Jozsef Aszodi, David Alan Rowlands, Claude Fromentin
  • Patent number: 7109357
    Abstract: Disclosed herein is a method for making compounds that are useful as caspase inhibitor prodrugs of formula I: wherein R1 is an optionally substituted group selected from an aliphatic group, aralkyl group, heterocyclylalkyl group or aryl group, and R2 is preferably a P2—P4 moiety of a caspase inhibitor.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: September 19, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marion W. Wannamaker, Cornelia Forster
  • Patent number: 7105568
    Abstract: The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: September 12, 2006
    Assignee: ARYx Therapeutics, Inc.
    Inventor: Pascal Druzgala
  • Patent number: 7101892
    Abstract: The present invention relates to sulfone derivatives of formula (I): Ar—SO2—CR2R3-L-N(R1)2I wherein Ar, L, R1, R2 and R3 are as defined herein, and pharmaceutically acceptable salts and N-oxides thereof, useful in the treatment of a condition which is susceptible to treatment by modulation of 5-HT7 receptor activity, such as depression or a sleep disorder.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: September 5, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Sylvie Bourrain, Peter Alan Hunt, Ian Thomas Huscroft, Janusz Jozef Kulagowski, Clare London, Elizabeth Mary Naylor, Piotr Antoni Raubo, Eileen Mary Seward
  • Patent number: 7101917
    Abstract: Methods of utilizing compounds of general formulas I and II as modulators and affinity labels of the MPTP complex are elucidated. Furthermore, methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent that modulates the activity of the MPTP complex, specifically methods for identifying an active agent that modulates the activity of the MPTP complex by interacting with the VDAC1 component are identified. Moreover, novel compounds of general formulas I and II are disclosed.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: September 5, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Andrea Cesura, Emmanuel Pinard
  • Patent number: 7102019
    Abstract: An ascorbic acid derivative of the formula Ia: where the variables independently of one another have the following meanings: R1 and R2 independently of one another are hydrogen or C1-C20-acyl; R3 is hydrogen or a cation selected from the group consisting of NH4+, alkali metal and alkaline earth metal cations; R4 is C1-C6-alkoxycarbonyl, and a process for its preparation.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: September 5, 2006
    Assignee: BASF Aktiengesellschaft
    Inventors: Harald Streicher, Bernd Ostersehlt, Horst Westenfelder
  • Patent number: 7098247
    Abstract: The present invention describes compounds of the general formula I as well as processes for their manufacture, pharmaceutical compositions containing them and methods for using these compounds and pharmaceutical compositions as pharmaceutical agents. The compounds according to this invention show antiproliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: August 29, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Frank Herting, Matthias Koerner, Manfred Kubbies, Anja Limberg, Ulrike Reiff, Michael Weidner